Adamis Pharmaceuticl (NQ: ADMP )
0.1200 +0.0153 (+14.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
All News about Adamis Pharmaceuticl
Adamis Pharmaceuticals Seeks Strategic Options, Including Sale
October 04, 2022
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) rose 43.2% to $0.2097 in pre-market trading after jumping over 16% on Tuesday. Adamis Pharmaceuticals recently announced a review of strategic...
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 11, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...
12 Health Care Stocks Moving In Monday's Intraday Session
October 03, 2022
Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy
September 21, 2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19...
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
September 12, 2022
Adamis Achieves Enrolment Target In Mid-Stage Covid-19 Study, Awaits Data Safety Monitoring Board Review Later This Month
September 12, 2022
Adamis Pharmaceuticals (NASDAQ: ADMP) announced that it has reached the initial planned enrollment target in the ongoing U.S. Phase 2/3 clinical trial investigating Tempol as a treatment for COVID-19.
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period...
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session
July 21, 2022
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending...
Blackberry Considers Alternative To Selling Catapults As Continuation Of Covid-19 Means More Room For Adamis Pharmaceuticals Corp.
June 01, 2022
As an alternative to the $600 million non-core intellectual asset transaction it had agreed to with Catapult IP Innovations, BlackBerry
Via Best Stocks
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following